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Accepted 29 May 2019; Published online 3 June 2019AbstractObjectives: Recruitment to pragmatic trials is often difficult, and little is known about factors associated with key participation and
treatment decisions. These were explored in the Prostate cancer testing and Treatment (ProtecT) study.
Study Design and Setting: Baseline sociodemographic, patient-reported outcome, clinical history, and prostate cancer biopsy data
were collected for all patients eligible to take part in the ProtecT trial, in a comprehensive cohort design. Men who rejected randomization
specified a preferred option and were followed up identically to the randomized cohort. Factors associated with participation decisions,
patient preferences, and reasons for changing treatment were explored.
Results: Of 2,664 men with clinically localized prostate cancer, 997 (37%) rejected randomization. Their treatment preferences and
subsequent treatment choices/changes in both randomized and treatment choice cohorts were strongly associated with prostate cancer risk
features: toward active monitoring for low-risk disease and toward radical options with higher risk prostate cancer. Among many factors
measured, only a small number of weak associations were found for occupation groups and some patient symptoms. Similar percentages
changed from the random allocation and initially stated preference.
Conclusion: The comprehensive cohort design provided new insights into trial recruitment and participation decisions. Opportunities to
improve recruitment by supporting recruiters with equipoise and patient preferences were identified.  2019 The Authors. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Randomization; Preferences; Randomized trial; Recruitment; Comprehensive cohort; Research participation1. Introduction
Randomized controlled trials (RCTs) are the design of
choice for evaluating the effectiveness of health-related in-
terventions because the process of randomization aims to
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0895-4356/ 2019 The Authors. Published by Elsevier Inc. This is an open acc
licenses/by-nc-nd/4.0/).recommend, or patients choose, specific treatment options.
However, it is common for pragmatic RCTs to experience
difficulties with recruitment, particularly when interven-
tions are very different, for example, where treatment op-
tions can be invasive, or unavailable in routine practice,
or involve a nonactive or monitoring strategy. RCT recruit-
ment should only occur when clinicians are sufficiently un-
certain (in ‘‘equipoise’’) about the optimal intervention for
a patient [1] and when patients have received clear informa-
tion that ensures they do not have strong preferences for a
particular option and can provide fully informed consent to
take part [2]. Equipoise and patient preferences are exam-
ples of ‘‘hidden challenges’’ to recruitment that are difficult
to elicit and measure [3]. Achieving equipoise in relation to
an individual patient remains difficult for clinicians, partic-
ularly if there is a conflict with their own beliefs aboutess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 In a comprehensive cohort study including all pa-
tients eligible for the Prostate testing for cancer
and Treatment trial, 1,643 (62%) agreed to be ran-
domized, and 997 men (37%) rejected randomiza-
tion and were followed up as a ‘‘treatment choice’’
cohort. Treatment preferences, changes of treat-
ment, and treatments received in the randomized
and treatment choice cohorts were strongly associ-
ated with prostate cancer risk features, with few
other associations.
 Percentages subsequently changing treatment from
the random allocation or initially stated preference
were very similar.
What this adds to what was known?
 This article contributes new insights that increase
our understanding of the role played by patient
preferences and clinician equipoise during recruit-
ment to pragmatic randomized controlled trials
(RCTs). It also identifies opportunities to address
some of the challenges to recruitment.
What is the implication and what should change
now?
 Interventions need to be developed or extended to
support recruiters with expressing equipoise and
understanding patient preferences.
 Comprehensive cohort studies could be undertaken
more often to investigate and address RCT recruit-
ment issues, particularly in areas of high public
health importance.
interventions and perceptions of risks they believe apply to
specific patients [4,5]. Strong patient preferences are also
frequently cited as a common and major barrier to RCT
recruitment [6e8], with concerns that the absence of large
numbers of patients who are eligible for an RCT but not re-
cruited will likely limit an RCT’s generalizability [9].
RCT designs that could enable the exploration of the in-
fluences of these issues include ‘‘comprehensive cohorts,’’
where patients are offered randomization, but those with
strong preferences can choose a treatment instead, with
all followed-up [10], or ‘‘preference’’ trials, where patients
are asked to report their preferences before or after they
have been randomized [11]. These designs are usually
considered a pragmatic approach when recruitment is diffi-
cult, and they have provided useful information about the
acceptability of options [12], rare or important outcomes
[13], and generalizability [14]. They are uncommon
J.L. Donovan et al. / Journal of Clibecause of resource constraints and difficulties analyzing
small randomized groups [15]. These designs provide op-
portunities to investigate recruitment decision-making and
selection biases between randomized and preference
groups, but these issues have been little considered in the
previously mentioned studies. Overall, very little is known
about these crucial aspects of the recruitment process in
RCTs. We were able to investigate these issues in the Pros-
tate testing for cancer and Treatment (ProtecT) comprehen-
sive cohort study and embedded RCT.
The ProtecT RCT compared three very different treat-
ments for clinically localized prostate cancer: active moni-
toring (a surveillance strategy), surgery (radical
prostatectomy), or radiotherapy (conformal external beam
with neoadjuvant androgen deprivation therapy). The
design of the ProtecT treatment RCT and baseline findings
of the randomized participants were reported in 2016 [16].
ProtecT RCT participants were recruited during a program
of population-based prostate-specific antigen (PSA) testing
[17]. Follow-up was undertaken within a comprehensive
cohort study design including all men diagnosed with pros-
tate cancer: those eligible for the RCT who either agreed to
be randomized or chose their treatment and those found to
be ineligible because of advanced prostate cancer or comor-
bidities. The design of the ProtecT comprehensive cohort
study, representativeness of the PSA-tested cohort, and
generalizability of the follow-up patient groups were re-
ported in 2018 [17].
The present study focuses on the recruitment and RCT
participation decisions of 1,643 patients who agreed to be
randomized in the ProtecT treatment RCT (‘‘randomized’’
cohort) and 997 who declined randomization and chose
their treatment (‘‘treatment choice’’ cohort). The aim of
the analysis was to understand RCT recruitment and selec-
tion issues associated with the expression of treatment
preferences, RCT participation, changes of management
after randomization or treatment choice, and final receipt
of primary treatment; assessed in the randomized and
treatment choice cohorts in the ProtecT comprehensive
cohort study.2. Methods
2.1. Study design and data collection
The design and recruitment methods of the ProtecT trial
have been published previously [16,17] and are described
in brief previously. As indicated, a program of
population-based PSA testing of more than 110,000 men
aged 50 to 69 years in the United Kingdom between June
1999 and January 2009 led to the detection of prostate can-
cer in 3,221 men, of whom 2,664 (83%) were eligible to
participate in the ProtecT treatment RCT comparing active
monitoring, surgery, or radiotherapy. The cancer diagnosis
was given by a consultant urologist who provided basic in-
formation about the RCT and an information sheet. Patients
202 J.L. Donovan et al. / Journal of Clinical Epidemiology 113 (2019) 200e213returned for a longer appointment with a trained nurse who
explained the details of the RCT and explored men’s treat-
ment preferences to ensure they reached an informed deci-
sion about whether or not to participate in the RCT. If men
agreed to be randomized, they were informed about the
allocation; if they declined to be randomized, they were
asked to specify their preferred option.
At the time of PSA testing, participants provided socio-
demographic and clinical history information and
completed a brief questionnaire containing generic and
condition-specific patient-reported outcome measures
(PROMs). They completed more detailed PROMs at the
prostate biopsy appointment, and clinicopathologic infor-
mation from biopsies was also recorded. Primary treatment
received was defined as the treatment starting/occurring
within 12 months of diagnosis (with at least two PSA tests
needed for receipt of active monitoring, and radiotherapy
was received if completed within 15 months) to ensure par-
ity between the randomized and ‘‘treatment choice’’ co-
horts. The only other major treatment received was
brachytherapy (this had different inclusion criteria). Any
other treatment, no treatment, or treatments received
outside the specified time window were categorized as
‘‘other.’’
Approval for the study was obtained from the UK East
Midlands (formerly Trent) Multicenter Research Ethics
Committee (01/4/025).2.2. Statistical methods
Associations between baseline sociodemographic, clin-
ical and PROMs data, clinicopathologic findings from bi-
opsy specimens, and the following were explored:
1. Consent to randomization or stating a treatment
preference
2. Changing from the random allocation or stated pref-
erence in randomized and treatment choice cohorts:
(a) to a more radical option (from active monitoring to
surgery or radiotherapy/brachytherapy) or
(b) to a less radical option (from surgery or radio-
therapy/brachytherapy to active monitoring)
3. Primary treatment received in randomized and treat-
ment choice cohorts (later changes of management
will be reported in future articles)
For (skewed) continuous sociodemographic outcomes,
medians and interquartile ranges were reported; continuous
outcomes from questionnaire data were presented with
means and standard deviations to identify ceiling effects.
KruskaleWallis tests were used to compare continuous
baseline characteristics across groups defined by treatment
received. For categorical outcomes, such as previous PSA
test, treatment received groups were compared using logis-
tic regression, followed by a postestimation Wald test to
compare the treatment groups or cohorts simultaneously[17]. Ordered categorical outcomes such as occupation
and cancer staging were analyzed using ordinal logistic
regression followed by a Wald test with the most desir-
able/least worst category as the base comparator/reference
group. PROMs were: generic health status (SF-12 [18]),
Hospital Anxiety and Depression scale ([19]), urinary
symptoms (ICSmaleSF [20] and Expanded Prostate Cancer
Index Composite [EPIC] urinary domain [21]), urinary in-
continence (ICIQ [22]), and sexual and bowel dysfunction
(EPIC [21]). These were analyzed as specified by their de-
velopers; categorical outcomes were dichotomized as
‘‘never’’ versus ‘‘ever.’’ Differences between the random-
ized and treatment choice cohorts were compared using
ManneWhitney tests and logistic regression and ordinal
regression models.
Given the exploratory nature of the study and large num-
ber of tests, greater attention was given to descriptive statis-
tics where the magnitude of effects was substantial, rather
than just relying on P values. Differences considered to
be of clinical importance (0.5 standard deviations or
10%) were also considered when evaluating the relation-
ship between baseline factors and treatment preferences
and changes. All statistical analyses were conducted using
STATA version 15.1 (StataCorp LLC, College Station, TX).3. Results
Of the 2,664 men diagnosed with clinically localized
prostate cancer who were eligible for the three-arm ProtecT
trial (24 randomized in a discontinued two-arm version
were excluded), 997 (37%) declined randomization
(Fig. 1 shows participant flow in the randomized and treat-
ment choice cohorts).
3.1. Randomized cohort
Overall, 1,273 (78%) of the 1,643 randomized partici-
pants received the random allocation as their primary treat-
ment (including brachytherapy as a form of radiotherapy).
More accepted the random allocation to active monitoring
457 (84%, 95% confidence interval [CI] 81e87) than to
surgery 397 (72%, 95% CI 68e76) or radiotherapy 419
(77%, 95% CI 73e80; Fig. 1). Most of those who did not
accept the random allocation opted for one of the three
RCT treatments (Table 1). Most switching from an alloca-
tion to radical treatment (surgery or radiotherapy) opted for
active monitoring, with smaller numbers changing to an
alternative radical option. Those changing from the active
monitoring allocation were twice as likely to opt for sur-
gery (n 5 49) as radiotherapy (n 5 25).
There was strong evidence that changing to a radical op-
tion was associated with having higher risk disease features
(including a higher PSA, higher cancer grade or stage, and
having a larger cancer with more positive cores at biopsy)
and changing to active monitoring was associated with
lower risk disease and not being married (Table 2).
2,664 men with localised prostate cancer 
(eligible) 
486
Active Monitoring (AM)
301
Surgery (RP)
134
Radiotherapy (RT)
1643 
Randomised in ProtecT trial 
997
Declined randomisation 
24 randomised in  
discontinued 2-arm study 
55  
Brachytherapy (BT) 
545  
Active Monitoring (AM) 
553 
Surgery (RP) 
545
Radiotherapy (RT) 
457 
Received 
rand  
397
Received 
rand  
78 
Switched  
138 
Switched  
49 RP 
976
Expressed initial preference 
21 did not make an initial 
preference 
10
Other 
18
Other 
408
Received 
rand  
129
Switched 
8
Other 
412
Received 
pref 
65
Received 
alt. 
9
Other 
197
Received 
pref 
91
Received 
alt. 
13
Other 
118
Received 
pref 
12
Received 
alt. 
4
Other 
45
Received 
pref 
6 
Received 
alt. 
4
Other 
25 RT 4 BT 95 AM 37 RT 6 BT 76 AM 42 RP 11 BT 55 RP 6 RT 4 BT 86 AM 5 RT 0 BT 5 AM 1 RP 6 BT 3 AM 1 RP 2 RT 
Fig. 1. Treatment preference and random allocation decisions in the ProtecT trial comprehensive cohort. a Excluded. b 8 received surgery, 1 AM, 2
radiotherapy, 1 brachytherapy, 6 withdrew, 2 other, 1 died before commencing treatment. c 6 received treatment outside time window, 1 another
treatment, 2 withdrew and 1 died before commencing treatment. d 13 received treatment outside time window, 3 another treatment and 2 with-
drew. e 7 received treatment outside time window and 1 withdrew. f 4 received treatment outside time window, 1 another treatment and 4 withdrew.
g 3 received treatment outside time window, 8 another treatment and 2 withdrew. h 3 received treatment outside time window and 1 another treat-
ment. i 1 received treatment outside time window, 1 another treatment and 2 withdrew.
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sional occupations were more likely to switch in either direc-
tion than other occupational groups, and that lower levels of
anxiety and depression were seen among thosewho changed.
Weak evidence suggested that men with urinary symptoms
that bothered them were more likely to switch to a radical
treatment and those with more bowel and sexual dysfunction
to switch to active monitoring (Table A2).Table 1. Treatment received compared with random allocation or initia
management
Treatment allocation or
preference Active monitoring, n (%) Radical prostatect
Random allocation
Active monitoring 457 (84) 49 (9)
Radical prostatectomy 95 (17) 397 (72
Radiotherapy 76 (14) 42 (8)
Initially expressed preference
Active monitoring 412 (86) 55 (11
Radical prostatectomy 86 (29) 197 (65
Radiotherapy 5 (4) 1 (1)
Brachytherapy 3 (5) 1 (2)
Other/none 1 (5) 8 (38
Bold face shows where the allocation or preference was the primary trea
a 6 outside time window, 1 another treatment, 2 withdrew, and 1 died
b 13 outside time window, 3 another treatment, and 2 withdrew.
c 7 outside time window and 1 withdrew.
d 4 outside time window, 1 another treatment, and 4 withdrew.
e 3 outside time window, 8 another treatment, and 2 withdrew.
f 3 outside time window and 1 another treatment.
g 1 outside time window, 1 another treatment, and 2 withdrew.3.2. Treatment choice cohort
Of the 997 men who declined randomization, almost all
(976) indicated a treatment option they preferred instead
(Fig. 1). They divided into 486 (50%) stating a preference
for active monitoring, and the remainder a radical option,
most opting for surgery 301 (31%), only 134 (14%) radio-
therapy, and 55 (6%) brachytherapy (Table 1). Overall, 780lly expressed preference, showing numbers switching or changing
Primary treatment received
omy, n (%) Radiotherapy, n (%) Brachytherapy, n (%) Other, n (%)
25 (5) 4 (1) 10 (2)a
) 37 (7) 6 (1) 18 (3)b
408 (75) 11 (2) 8 (1)c
) 6 (1) 4 (1) 9 (2)d
) 5 (2) 0 (0) 13 (4)e
118 (88) 6 (4) 4 (3)f
2 (4) 45 (82) 4 (7)g
) 2 (10) 1 (5) 9 (43)
tment received.
before commencing treatment.
Table 2. Baseline sociodemographic and clinical factors for those who agreed to be randomized and then received the random allocation or switched
to active monitoring or a radical option
Baseline factor
Switched to radical treatmenta
(n [ 78)
Switched to active monitoringb
(n [ 171)
Received random allocation
(n [ 1,273)
Age n 5 78 n 5 171 n 5 1,273
Median age (IQR) 60.0 (57.0, 64.0) 63.0 (58.0, 66.0) 62.0 (58.0, 66.0)
P value P 5 0.016
Ethnicity
White, n (%) 76 (97) 166 (97) 1,247 (99)
Other, n (%) 2 (3) 5 (3) 11 (1)
P value P 5 0.051
Marital status
Married/living as married, n (%) 68 (87) 128 (75) 1,079 (85)
Other (e.g., divorced), n (%) 10 (13) 43 (25) 183 (15)
P value P 5 0.001
Occupation (present or last paid)
Managerial, n (%) 40 (52) 77 (45) 517 (41)
Intermediate, n (%) 8 (10) 30 (18) 199 (16)
Working, n (%) 29 (38) 63 (37) 539 (43)
P value P 5 0.154
Cancer/treatment history
Previous PSA test, n (%) 12 (16) 22 (13) 172 (14)
P value P 5 0.864
Previous urinary/prostate treatment,
n (%)
3 (4) 15 (9) 114 (9)
P value P 5 0.311
Family history of cancer (prostate only),
n (%)
7 (10) 10 (7) 91 (8)
P value P 5 0.709
Family history of cancer (all), n (%) 42 (55) 79 (50) 719 (60)
P value P 5 0.047
Deprivation score n 5 76 n 5 170 n 5 1,259
Living in an area of deprivation, n (%) 8 (11) 20 (12) 196 (16)
P value P 5 0.237
PSA level (minimum n) n 5 78 n 5 169 n 5 1,263
Median baseline PSA level (IQR) 6.1 (4.1, 8.5) 4.4 (3.5, 6.6) 4.6 (3.6, 6.5)
P value P ! 0.001
Median biopsy PSA level (IQR) 6.3 (4.0, 9.3) 4.5 (3.5, 6.6) 4.7 (3.6, 6.8)
P value P ! 0.001
Gleason (aggressiveness) score, n (%)
6 53 (68) 145 (85) 977 (77)
7 20 (27) 24 (14) 271 (21)
8e10 5 (6) 2 (1) 25 (2)
P value P 5 0.006
Cancer staging, n (%)
T1 54 (69) 142 (83) 965 (76)
T2 24 (31) 29 (17) 308 (24)
P value P 5 0.038
Cancer riskc, n (%)
Low 31 (40) 117 (68) 737 (58)
Intermediate 42 (54) 52 (30) 511 (40)
High 5 (6) 2 (1) 25 (2)
P value P ! 0.001
(Continued )
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Table 2. Continued
Baseline factor
Switched to radical treatmenta
(n [ 78)
Switched to active monitoringb
(n [ 171)
Received random allocation
(n [ 1,273)
Biopsy cores invaded with cancer, n (%)
1 17 (22) 58 (34) 410 (33)
2 17 (22) 48 (28) 248 (20)
3þ 44 (56) 63 (37) 601 (48)
P value P 5 0.028
Perineural invasion
No (%) 59 (76) 145 (85) 1,002 (80)
Yes (%) 19 (24) 25 (15) 249 (20)
P value P 5 0.154
Length of tumors (minimum n) n 5 72 n 5 150 n 5 1,157
Medium maximum length (mm) in any
one core (IQR)
4.0 (2.0, 6.0) 2.0 (1.0, 4.0) 3.0 (1.0, 6.0)
P value P ! 0.001
Median aggregate length (mm) of
tumors (IQR)
6.5 (2.0, 13.0) 3.0 (1.0, 6.5) 4.0 (2.0, 11.0)
P value P ! 0.001
Abbreviations: IQR, interquartile range; PSA, prostate-specific antigen.
P values are three-way comparisons, using a logistic or ordinal logistic model followed by a Wald test for categorical outcomes and a
KruskaleWallis test for continuous outcomes.
a Moving from an initial preference of active monitoring to receiving radical prostatectomy, radiotherapy, or brachytherapy.
b Moving from an initial preference of radical prostatectomy, radiotherapy, or brachytherapy to receiving active monitoring.
c Risk was defined as ‘‘Low’’ if T1 and G  6 and pccPSA ! 10, ‘‘High’’ if G  8, and ‘‘Intermediate’’ for all other combinations of stage,
grade, and PSA.
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pressed a preference for (combining radiotherapy and
brachytherapy)da similar percentage as the 78% who
received their random allocation (as mentioned earlier).
High percentages of those indicating a preference for
active monitoring (85%, 95% CI 82e88), radiotherapy
(93%, 95% CI 88e97), or brachytherapy (85%, 95% CI
76e95) went on to receive that option (82%e88%),
whereas a much smaller percentage went on to receive
their initial preference for surgery (65%). The relatively
small numbers who changed from a preference for active
monitoring, radiotherapy, or brachytherapy received
similar options to those switching from the random alloca-
tion, whereas the majority of those who changed from an
initial preference for surgery received active monitoring
(86/104).
There was weak evidence that those with managerial oc-
cupations were more likely to change from their initial
preference (in either direction) compared with those in
other occupations. There was stronger evidence that chang-
ing from their preference was associated with clinical fac-
tors relating to their cancerdwith those moving to radical
options having higher risk disease, whereas those moving
to active monitoring tended to have lower risk cancer fea-
tures (Table 3). There was no evidence that anxiety or
depression or sexual or bowel symptoms were associated
with changing, although lower levels of urinary symptoms
interfering with life were associated with changing to active
monitoring (Table A3).3.3. Factors associated with primary treatment received
There was some evidence of movement toward surgery/
radiotherapy for those with higher risk cancer and toward
active monitoring for those with lower risk disease in rela-
tion to treatments received in the randomized cohort
(Table 4 and Table A4). Those opting for brachytherapy
were a small (n 5 21) and a highly selected group of
younger men mostly with professional/managerial occupa-
tions and lower risk disease (reflecting the narrower eligi-
bility criteria for this treatment).
The treatment choice cohort groups were not as well
balanced in numbers or baseline factors as the randomized
[16]: 507 (52%) received active monitoring, 262 (27%) sur-
gery, 133 (13%) radiotherapy, 56 (6%) brachytherapy, and
39 ‘‘others’’ (11 received treatment outside the time win-
dow, 14 withdrew, 1 died, and 13 received another treat-
ment; Fig. 1). There was evidence that occupation type
and cancer risk features were associated with the receipt
of particular primary treatment options (Table 5). Men
who received active monitoring had the least severe disease
features, whereas those who received surgery or radio-
therapy were more likely to have higher risk disease with
more adverse features at biopsy. Those receiving brachy-
therapy were more likely to have had a PSA test previously
(29%), have the lowest risk disease, and to be in manage-
rial/professional occupations (80%), contrasting particu-
larly with only 36% who received radiotherapy. There
was little evidence of associations between PROMs and
Table 3. Baseline sociodemographic and clinical factors of those who declined randomization and expressed an initial preference and then either
received their original preference or changed to another option
Baseline factor
Changed to a radical treatmenta
(n [ 65)
Changed to active monitoringb
(n [ 94)
Received original preference
(n [ 780)
Age n 5 65 n 5 94 n 5 780
Median age (IQR) 62.0 (57.0, 65.0) 62.0 (58.0, 65.0) 62.0 (58.0, 65.0)
P value P 5 0.862
Ethnicity
White, n (%) 63 (98) 93 (99) 771 (99)
Other, n (%) 1 (2) 1 (1) 6 (1)
P value P 5 0.790
Marital status
Married/living as married, n (%) 52 (81) 76 (81) 661 (85)
Other (e.g., divorced), n (%) 12 (19) 18 (19) 115 (15)
P value P 5 0.420
Occupation (present or last paid)
Managerial, n (%) 40 (63) 55 (61) 382 (50)
Intermediate, n (%) 8 (13) 12 (13) 126 (16)
Working, n (%) 16 (25) 23 (26) 260 (34)
P value P 5 0.030
Cancer/treatment history, n (%)
Previous PSA test 9 (14) 14 (15) 140 (18)
P value P 5 0.604
Previous urinary/prostate treatment 4 (6) 7 (8) 64 (8)
P value P 5 0.850
Family history of cancer (prostate only) 7 (13) 8 (10) 64 (9)
P value P 5 0.710
Family history of cancer (all) 36 (59) 50 (57) 430 (59)
P value P 5 0.939
Deprivation score (n) n 5 63 n 5 92 n 5 765
Living in an area of deprivation, n (%) 7 (11) 12 (13) 87 (11)
P value P 5 0.889
PSA level (minimum n) n 5 52 n 5 82 n 5 697
Median baseline PSA level (IQR) 5.6 (3.7, 7.7)
P value P 5 0.093
Median biopsy PSA level (IQR) 6.0 (4.1, 8.1) 4.6 (3.6, 5.8) 4.7 (3.6, 6.8)
P value P 5 0.211 4.8 (3.8, 6.2) 4.7 (3.6, 6.9)
Gleason score, n (%)
6 45 (70) 81 (86) 585 (75)
7 17 (27) 12 (23) 179 (23)
8e10 2 (3) 1 (1) 15 (2)
P value P 5 0.037
Cancer staging
T1 46 (71) 74 (79) 596 (76)
T2 19 (29) 20 (21) 184 (24)
P value P 5 0.497
Cancer risk,c n (%)
Low 31 (48) 64 (68) 432 (55)
Intermediate 31 (48) 29 (31) 332 (43)
High 2 (3) 1 (1) 15 (2)
P value P 5 0.027
Biopsy cores invaded with cancer, n (%)
1 20 (32) 33 (37) 250 (33)
(Continued )
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Table 3. Continued
Baseline factor
Changed to a radical treatmenta
(n [ 65)
Changed to active monitoringb
(n [ 94)
Received original preference
(n [ 780)
2 13 (20) 20 (22) 147 (19)
3þ 31 (48) 36 (40) 369 (48)
P value P 5 0.446
Perineural invasion
No (%) 54 (83) 77 (86) 595 (78)
Yes (%) 11 (17) 13 (14) 163 (22)
P value P 5 0.227
Length of tumors, (minimum n) n 5 58 n 5 83 n 5 711
Medium maximum length (mm) in any
1 core (IQR)
3.0 (1.0, 6.0) 2.0 (1.0, 5.0) 3.0 (1.0, 6.0)
P value P 5 0.718
Median aggregate length (mm) of
tumors (IQR)
5.0 (2.0, 17.0) 4.0 (1.5, 9.0) 4.0 (2.0, 12.0)
P value P 5 0.238
Abbreviations: IQR, interquartile range; PSA, prostate-specific antigen.
P values are three-way comparisons, using a logistic or ordinal logistic model followed by a Wald test for categorical outcomes and a
KruskaleWallis test for continuous outcomes.
a Moving from an initial preference of active monitoring to receiving radical prostatectomy, radiotherapy, or brachytherapy.
b Moving from an initial preference of radical prostatectomy, radiotherapy, or brachytherapy to receiving active monitoring.
c Risk was defined as ‘‘Low’’ if T1 and G  6 and pccPSA ! 10, ‘‘High’’ if G  8, and ‘‘Intermediate’’ for all other combinations of stage,
grade, and PSA.
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men who received surgery or radiotherapy had slightly
worse urinary symptoms (Table A5).4. Discussion
This analysis of all patients eligible for the ProtecT ran-
domized trial of treatments for clinically localized prostate
cancer has provided new insights into trial recruitment,
particularly about treatment preferences and key decisions
about participation and changes after randomization. Over-
all, the randomized and treatment choice groups in the Pro-
tecT comprehensive cohort were very similar in relation to
most baseline data except that those who chose a treatment
were more likely to be in managerial/professional occupa-
tions and to have had a previous PSA test [17]. Among
those who rejected randomization, more chose active moni-
toring than the other options, and these preferences were
associated with low-risk disease. Preferences for radical
treatments were associated with higher risk disease. A very
similar percentage switched treatment from their random
allocation (22%) as changed from an initially stated prefer-
ence (20%). These changes were also associated with the
same pattern of cancer risk features and occupation type.
There was weaker evidence that men in managerial/profes-
sional occupations were more likely than those in other
occupation groups to change from the random allocation,
but stronger evidence they were more likely to change
from their initial preference to another treatment and
choose options only available outside the RCT, such as
brachytherapy.There were only a small number of examples where
there was some evidence that factors captured by PROMs
appeared to influence decision-making, for example, weak
evidence that men with lower levels of anxiety and depres-
sion or some bowel and sexual symptoms were more likely
to change to active monitoring and some with bothersome
urinary symptoms to opt for a radical option. The groups
defined according to treatments received also reflected the
influences of selection by prostate cancer risk features
and occupation type.
The ProtecT trial provided the opportunity to investigate
the influences of baseline factors on RCT participation de-
cisions because of its comprehensive cohort design and a
recruitment intervention that included active discussion of
treatment preferences [17,23,24]. In most RCTs, data are
primarily (sometimes only) available for those who have
agreed to be randomized, with little, if any, consideration
of those not participating. In ProtecT, the treatment RCT
was preceded by a program of population-based PSA
testing, which included the collection of detailed baseline
sociodemographic, clinical history, biopsy, and PROMs
data on all men later diagnosed with localized prostate can-
cer and deemed eligible for the RCT (n 5 2,664). A large
proportiond1,643 men (62%)dagreed to be randomized
between surgery, radiotherapy, and active monitoring, and
the 997 who declined randomization had their treatment
preference recorded and were followed up in the same
way as the randomized. Other comprehensive cohort
studies have tended to have small randomized cohorts
[10] or were used to explore rarer outcomes [13] or gener-
alizability [14]. To our knowledge, this is the first time that
Table 4. Baseline sociodemographic and clinical factors of those who accepted randomization, according to primary treatment received (regardless
of randomized allocation) within 12 months
Baseline factor
Active monitoring
(n [ 628)
Surgery
(n [ 488)
Radiotherapy
(n [ 470)
Brachytherapy
(n [ 21)
Age (n) n 5 628 n 5 488 n 5 470 n 5 21
Median age (IQR) 62.0 (58.0, 66.0) 61.0 (57.0, 65.0) 62.0 (58.0, 66.0) 59.0 (53.0, 62.0)
P value P 5 0.005
Ethnicity
White, n (%) 615 (99) 477 (98) 459 (99) 21 (100)
Other, n (%) 8 (1) 8 (2) 4 (1) 0 (0)
P value P 5 0.567
Marital status, n (%)
Married/living as married 511 (82) 416 (86) 405 (87) 16 (76)
Other (e.g., divorced) 114 (18) 67 (14) 62 (13) 5 (24)
P value P 5 0.062
Occupation (present or last paid), n (%)
Managerial 260 (42) 207 (43) 189 (41) 15 (71)
Intermediate 100 (16) 65 (13) 85 (18) 1 (5)
Working 261 (42) 210 (44) 187 (41) 5 (24)
P value P 5 0.130
Cancer/treatment history, n (%)
Previous PSA test 80 (13) 75 (16) 63 (14) 5 (25)
P value P 5 0.333
Previous urinary/prostate treatment 61 (10) 45 (9) 32 (7) 3 (15)
P value P 5 0.257
Family history of cancer (prostate only) 45 (8) 34 (8) 38 (9) 1 (5)
P value P 5 0.837
Family history of cancer (all) 339 (58) 273 (59) 259 (59) 9 (45)
P value P 5 0.636
Deprivation score, n (%)
Living in an area of deprivation 95 (15) 78 (16) 62 (13) 1 (5)
P value P 5 0.410
PSA level (minimum n) n 5 628 n 5 488 n 5 470 n 5 21
Median baseline PSA level (IQR) 4.4 (3.6, 6.4) 4.7 (3.7, 6.9) 4.8 (3.7, 6.9) 4.3 (3.5, 5.7)
P value P 5 0.041
Median biopsy PSA level (IQR) 4.5 (3.5, 6.6) 5.1 (3.7, 7.3) 4.9 (3.6, 7.4) 4.2 (3.3, 4.8)
P value P 5 0.004
Gleason score, n (%)
6 503 (80) 366 (75) 352 (75) 18 (86)
7 116 (18) 112 (23) 103 (22) 3 (14)
8e10 9 (1) 10 (2) 15 (3) 0 (0)
P value P 5 0.074
Cancer staging, n (%)
T1 491 (78) 361 (74) 351 (75) 19 (90)
T2 137 (22) 127 (26) 119 (25) 2 (10)
P value P 5 0.147
Cancer riska
Low 382 (61) 271 (56) 265 (56) 14 (67)
Intermediate 237 (38) 207 (42) 190 (40) 7 (33)
High 9 (1) 10 (2) 15 (3) 0 (0)
P value P 5 0.145
(Continued )
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Table 4. Continued
Baseline factor
Active monitoring
(n [ 628)
Surgery
(n [ 488)
Radiotherapy
(n [ 470)
Brachytherapy
(n [ 21)
Biopsy cores invaded with cancer, n (%)
1 203 (33) 152 (32) 141 (30) 6 (29)
2 136 (22) 91 (19) 94 (20) 7 (33)
3þ 281 (45) 238 (49) 232 (50) 8 (38)
P value P 5 0.530
Perineural invasion, n (%)
No 503 (81) 376 (79) 365 (78) 18 (86)
Yes 115 (19) 101 (21) 101 (22) 3 (14)
P value P 5 0.508
Length of tumors (minimum n) n 5 569 n 5 439 n 5 428 n 5 18
Medium maximum length (mm) in any
1 core (IQR)
2.0 (1.0, 5.0) 3.0 (1.0, 6.0) 3.0 (1.0, 6.0) 2.5 (2.0, 4.0)
P value P 5 0.229
Median aggregate length (mm) of
tumors (IQR)
4.0 (2.0, 10.0) 5.0 (2.0, 12.0) 5.0 (2.0, 13.0) 4.0 (3.0, 10.0)
P value P 5 0.184
Abbreviations: IQR, interquartile range; PSA, prostate-specific antigen.
P values are four-way comparisons, using a logistic or ordinal logistic model followed by a Wald test for categorical outcomes and a
KruskaleWallis test for continuous outcomes.
a Risk was defined as ‘‘low’’ if T1 and G  6 and pccPSA! 10, ‘‘high’’ if G  8, and ‘‘intermediate’’ for all other combinations of stage, grade,
and PSA.
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and participation decisions have been so comprehensively
investigated.
Although many baseline socioeconomic, clinical history,
biopsy findings, and PROMs data were collected, only can-
cer risk features were strongly and consistently associated
with decision-making. However, there was weaker evidence
that men in managerial/professional occupations were more
likely to exercise choices at each stage of research partici-
pation than men in other occupational groups. They were
more likely than those in other occupations to respond
and agree to participate during the PSA testing and diag-
nostic program [17], more likely to reject randomization
and choose their preferred treatment, and also to change
their minds after their initially stated preference. They
changed in both directions: to active monitoring from a
radical option and from a radical option to active moni-
toring. They were also more likely to actively seek options
outside usual practiceda PSA test before the ProtecT invi-
tation [17]dor brachytherapy, not available in the RCT.
Previous research has identified employment status and
level of education as factors associated with treatment pref-
erences and participation in RCTs, although usually in rela-
tion to underparticipation of more deprived groups [25].
However, if the findings shown here are occurring in other
RCTs, this may explain some fraction of the poor RCT
recruitment seen more generally. This novel finding needs
to be investigated in other RCTs. It suggests a potential need
for targeted information for this group (those with manage-
rial/professional occupations) so that they can better under-
stand the rationale for RCTs and randomization.Selection by prostate cancer risk features was also seen
in the treatments received cohort. Observational studies
also typically show that surgery and radiotherapy are
received by men with higher risk disease and active surveil-
lance by men with lower risk disease and also that lower in-
come/education/occupation groups tend to receive
radiotherapy [26e28]. Younger fitter men have tended to
receive surgery, and older less fit men receive radiotherapy
in observational studies, whereas in ProtecT, the treatment
groups were very similar in age and fitness [16]. This and
other unmeasured confounding might explain why the su-
periority of surgery over radiotherapy in terms of mortality
and cancer outcomes seen in observational studies [26] was
not seen in the ProtecT trial primary analysis at a median of
10 years [29].
Patients’ treatment preferences are usually considered to
make recruitment difficult [6,7] and increase switching
[30]. Previous research in ProtecT, however, showed that
when recruiters gently explored and addressed initially ex-
pressed preferences, the numbers of patients willing to
consider randomization increased and numbers later
switching were reduced [23,24,31]. Research suggesting
that treatment preferences are often constructed during elic-
itation and are sensitive to contextual factors supports this
approach [32].
Recruitment in ProtecT was guided by a complex inter-
vention [24]. A high percentage of eligible patients agreed
to be randomized (62%) compared with around 20% in a
similar RCT [33]. The randomized and treatment choice
cohorts had very similar baseline data, there were consis-
tent and plausible factors associated with treatment
Table 5. Baseline sociodemographic and clinical factors of those who declined randomization and chose their treatment, according to primary
treatment received within 12 mo
Baseline factor
Active monitoring
(n [ 507)
Surgery
(n [ 262)
Radiotherapy
(n [ 133)
Brachytherapy
(n [ 56)
Age (n) n 5 507 n 5 262 n 5 133 n 5 56
Median age (IQR) 62.0 (58.0, 65.0) 62.0 (58.0, 65.0) 62.0 (58.0, 65.0) 60.5 (56.0, 64.0)
P value P 5 0.004
Ethnicity, n (%)
White 500 (99) 259 (100) 131 (99) 56 (100)
Other 6 (1) 1 (0) 1 (1) 0 (0)
P value P 5 0.557
Marital status, n (%)
Married/living as married 419 (83) 231 (89) 108 (82) 50 (89)
Other (e.g., divorced) 87 (17) 29 (11) 23 (18) 6 (11)
P value P 5 0.102
Occupation (present or last paid), n (%)
Managerial 256 (52) 142 (55) 48 (36) 43 (80)
Intermediate 82 (17) 38 (15) 24 (18) 7 (13)
Working 158 (32) 79 (31) 60 (45) 4 (7)
P value P ! 0.001
Cancer/treatment history, n (%)
Previous PSA test 76 (15) 58 (22) 17 (13) 16 (29)
P value P 5 0.007
Previous urinary/prostate treatment 33 (7) 25 (10) 15 (11) 5 (9)
P value P 5 0.232
Family history of cancer (prostate only) 42 (9) 25 (11) 9 (8) 5 (10)
P value P 5 0.876
Family history of cancer (all) 277 (58) 151 (61) 68 (56) 29 (55)
P value P 5 0.731
Deprivation score, n (%)
Living in an area of deprivation 60 (12) 32 (12) 11 (9) 4 (7)
P value P 5 0.511
PSA level (minimum n) n 5 461 n 5 233 n 5 110 n 5 41
Median baseline PSA level (IQR) 4.6 (3.5, 6.5) 4.9 (3.7, 6.8) 5.4 (4.0, 8.0) 4.3 (3.5, 5.9)
P value P 5 0.002
Median biopsy PSA level (IQR) 4.7 (3.6, 6.7) 4.9 (3.7, 7.5) 5.1 (3.9, 7.5) 4.2 (3.4, 6.4)
P value P 5 0.064
Gleason score, n (%)
6 417 (82) 184 (71) 87 (65) 36 (63)
7 88 (17) 67 (26) 39 (29) 20 (35)
8e10 2 (!1) 9 (3) 7 (5) 1 (2)
P value P ! 0.001
Cancer staging, n (%)
T1 399 (79) 191 (73) 95 (71) 44 (79)
T2 108 (21) 71 (27) 38 (29) 12 (21)
P value P 5 0.164
Cancer riska
Low 321 (63) 138 (53) 52 (39) 26 (46)
Intermediate 184 (36) 113 (43) 74 (56) 30 (54)
High 2 (!1) 9 (3) 7 (5) 0 (0)
P value P ! 0.001
(Continued )
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Table 5. Continued
Baseline factor
Active monitoring
(n [ 507)
Surgery
(n [ 262)
Radiotherapy
(n [ 133)
Brachytherapy
(n [ 56)
Biopsy cores invaded with cancer, n (%)
1 198 (40) 69 (27) 30 (23) 12 (21)
2 97 (20) 44 (17) 27 (20) 16 (29)
3þ 201 (41) 140 (55) 76 (57) 28 (50)
P value P ! 0.001
Perineural invasion, n (%)
No 414 (84) 191 (75) 92 (69) 41 (31)
Yes 9 (16) 62 (25) 41 (31) 41 (31)
P value P 5 0.001
Length of tumors (minimum n) n 5 471 n 5 223 n 5 125 n 5 50
Medium maximum length (mm) in any
1 core (IQR)
2.0 (1.0, 5.0) 3.0 (1.0, 6.0) 4.0 (2.0, 7.0) 3.0 (1.0, 6.0)
P value P ! 0.001
Median aggregate length (mm) of
tumors (IQR)
3.0 (1.0, 8.5) 5.0 (2.0, 13.0) 6.0 (2.3, 15.8) 4.0 (2.0, 12.0)
P value P ! 0.001
Abbreviations: IQR, interquartile range; PSA, prostate-specific antigen.
P values are four-way comparisons, using a logistic or ordinal logistic model followed by a Wald test for categorical outcomes and a Kruskal
Wallis test for continuous outcomes.
a Risk was defined as ‘‘low’’ if T1 and G  6 and pccPSA!10, ‘‘high’’ if G  8 and ‘‘intermediate’’ for all other combinations of stage, grade,
and PSA.
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age changed from the allocation as from an initial prefer-
ence. The consistency of the findings in relation to risk
categorization and occupation type permits some specula-
tion about preferences in the treatment choice cohort. It
may have been that men in managerial/professional occu-
pations enquired about the details of their biopsy findings
and used these to form their preferences. It is also possible
that once patients declined randomization, their appoint-
ments became more like usual clinical practice, with clini-
cians using biopsy findings and risk categorization
alongside a patient’s preferences to reach ‘‘clinically appro-
priate’’ shared decisions [3]. The ‘‘clinical influence’’
might also account for surgery being chosen much more
frequently as a radical option than radiotherapy (lead inves-
tigators were mostly surgeons), and the majority of men
with small volume low-risk disease gravitating toward
active monitoring. A combination of these factors is prob-
ably most likely. In other RCTs, patients’ preferences have
also been observed to be accepted quickly if they accord
with clinicians’ views [5,31,34]. These findings suggest that
interventions to support clinicians with equipoise and
exploring patient preferences could improve RCT recruit-
ment more widely. However, these speculations require
further investigation.
The strengths of this study relate to the use of a compre-
hensive cohort RCT design, recruitment intervention, and
wide range of available data enabling detailed investigation
of RCT participation decisions. Limitations include that the
study was embedded in one RCT, and therefore, the partic-
ular features of ProtecT, including the disease area and highrandomization rate, may not have relevance for other RCTs.
In addition, associations with many data items were tested;
positive findings require replication or further investigation
in other RCTs.
In terms of future research, this article has identified op-
portunities to improve recruitment. The comprehensive
cohort design could be used more often for this purpose,
although its resource requirements may limit it to major
questions of public health importance or controversy. More
research is needed to better understand the effects of patient
preferences and equipoise on RCT recruitment, potentially
including further developing the recruitment intervention
initiated in ProtecT to support recruiters with these chal-
lenges [35]. More research is also needed to investigate
whether those in professional/managerial occupations are
also rejecting randomization more often in other RCTs
and need different information.5. Conclusion
The treatment choice and treatment-received cohorts in
the ProtecT study reflected prostate cancer disease selection
factors: active monitoring being associated with lower risk
disease and surgery/radiotherapy with intermediate- and
high-risk diseases. There were few examples where other
factors, including those captured by PROMs, influenced
decision-making. As cancer risk features reflect biopsy
findings, there may have been an interplay between men
in managerial/professional occupations using these details
to exercise their preferences, and clinicians steering pa-
tients toward clinically appropriate choices. These findings
212 J.L. Donovan et al. / Journal of Clinical Epidemiology 113 (2019) 200e213also suggest a renewed role for comprehensive cohort
studies and provide new insights to enable the development
or extension of interventions to support recruiters with is-
sues of equipoise and preferences to improve RCT
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